Tikun Olam is the world’s first licensed medical cannabis provider, established in Israel in 2005.
Through continuous research, patient care, and innovation, we have built one of the largest clinical datasets in the field, with more than 20,000 unique patient records.
Backed by multiple peer-reviewed studies and strain-specific clinical trials, our research has shaped the foundation of modern medical cannabis and continues to guide the standardized formulas trusted by patients and physicians worldwide.
Professor Raphael Mechoulam was instrumental in Tikun Olam’s earliest years, guiding the development of our signature strains within Israel’s pioneering medical cannabis program.
Recognized worldwide as the “Godfather of Cannabis Research”, he was the first to isolate and characterize THC, shaping compassionate-access programs and laying the scientific foundation of modern medical cannabis.
His vision remains deeply embedded in our roots, continuing to drive our mission.
Built on pioneering science, patient care, and international research progress, Tikun Olam’s achievements span landmark discoveries, clinical breakthroughs, and global expansion, setting the standards that define modern cannabis medicine worldwide.
Discovery of THC: Dr. Raphael Mechoulam, future advisor to Tikun Olam, and his team discover and isolate the THC molecule.
First patient care: Tikun Olam begins cultivating and distributing medical cannabis to patients in Israel.
First cannabis license: Tikun Olam is granted the first government license in Israel to produce and dispense medical cannabis.
Avidekel developed: Tikun Olam breeds Avidekel, its award-winning high-CBD strain known worldwide as “highless marijuana”.
Crohn’s breakthrough: Tikun Olam completes the world’s first randomized double-blind cannabis clinical trial for Crohn’s disease.
US market entry: Tikun Olam opens its first market test in the United States and realizes sales in Delaware.
Canada partnership: Tikun Olam partners with MedReleaf, bringing its strains to patients in Canada.
European expansion: Tikun Olam Greece opens Europe’s largest pharmaceutical cannabis cultivation facility.
New era of excellence: Tikun Olam accelerates research and launches its most advanced product line, setting a new standard in medical cannabis innovation.
2025
Award-winning proprietary Israeli strains optimized for targeted relief.
One of the world’s largest treatment databases, with more than 20,000 unique patient records collected through direct care.
More than two decades of clinical trials and laboratory studies on conditions such as cancer pain, IBD, Parkinson’s, and Tourette’s.
The world’s only successful Phase II double-blind cannabis clinical trial for Crohn’s disease.
Avidekel, a high-CBD strain, recognized as the first “highless marijuana” by Reuters.
Proprietary formulation and extraction methods ensuring consistent results.
Serving tens of thousands of patients worldwide through clinical programs and partnerships.
From Israel to The United States, Canada, and Europe, Tikun Olam has grown into the world’s leading medical cannabis research and treatment network.
Through clinical partnerships and patient care programs, our therapies now reach tens of thousands of patients worldwide, supported by the same standards of science, safety, and consistency that continue to define our work today.
Be first to get early access to insights, physician tips, events, and product updates.
By creating an account using email, I agree to the Terms & Conditions, and acknowledge the Privacy Policy.
These statements have not been evaluated by the FDA. Tikun Olam products are not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare provider before use.
GOVERNMENT WARNING: THIS WEBSITE DISCUSSES CANNABIS PRODUCTS. KEEP OUT OF REACH OF CHILDREN AND ANIMALS. CANNABIS PRODUCTS MAY ONLY BE POSSESSED OR CONSUMED BY PERSONS 21 YEARS OF AGE OR OLDER UNLESS THE PERSON IS A QUALIFIED PATIENT. THE INTOXICATING EFFECTS OF CANNABIS PRODUCTS MAY BE DELAYED UP TO TWO HOURS. CANNABIS USE WHILE PREGNANT OR BREASTFEEDING MAY BE HARMFUL. CONSUMPTION OF CANNABIS PRODUCTS IMPAIRS YOUR ABILITY TO DRIVE AND OPERATE MACHINERY. PLEASE USE EXTREME CAUTION.
Proposition 65 WARNING: This site may reference products that can expose you to cannabis smoke and Δ9-THC, chemicals known to the State of California to cause cancer and birth defects or other reproductive harm. For more information, visit P65Warnings.ca.gov/cannabis.
No sales on this site. Products are available only at licensed California dispensaries. You must be 21+ (or 18+ with a valid physician recommendation) to view product information.
Responsible licensee/advertiser: Tikun Olam LLC • Distribution License C11-0000181-LIC • Manufacturing License CDPH-10003257
Copyright © 2025 Tikun Olam LLC. All rights reserved.

































